ENGLISH
|
HINDI
APPS
iPhone
|
iPad
|
BlackBerry
|
Android
Nokia
Windows
Network18
Quotes
Quotes
NAVs
News
Messages
People
Notices
Videos
All
FEEDBACK
Facebook
Follow @moneycontrolcom on Twitter
CNBC TV 18
moneycontrol
News
Markets
Mutual Funds
IPO
Commodities
Wealth
Portfolio
Messages
My TV
Tax
Fixed Income
Property
SME
CNBC-TV18
Home
Business
General News
Market Trends
Stocks
Fund News
Personal Finance
Corporate Strategy
Lifestyle
Politics
Legal
Master Your Money
Share
>
Share
Tweet
Share on Tumblr
Salutas
News »
latest
by relevance
DRL sees FY09 revenues up 25% at Rs 6250 cr
Sep 12, 2008 at 15:45 | Source:
NewsWire18
Saumen Chakraborty, CFO, Dr Reddy's sees his company's FY09 revenues up by 25% at Rs 6,250 crore, reports CNBC-TV18, quoting NewsWire18. He said that the Dow and BASF units will add Rs 220 crore to FY09 revenues. He feels that the pressure in Europe is still a worry. The company will end pact with German company Salutas in October, he said.
DRL targets 25% rev growth in FY09
May 20, 2008 at 19:35 | Source:
CNBC-TV18
Satish Reddy, MD, Dr Reddy's Labs said that dependence on SALUTAS has significantly reduced, especially in the last quarter. He expects the company to grow at 25% in FY09, without any of the upsides or exceptional items.
Not dependent on SALUTAS any more: DRL
May 20, 2008 at 17:57 | Source:
CNBC-TV18
GV Prasad, VC & CEO, Dr Reddy's Labs said it is not dependent on SALUTAS any more, reports CNBC-TV18. "We will see improvement in the coming quarters. The Custom Pharmaceutical Services, or CPS, involves making drugs and ingredients specifically for other companies, business saw a de-growth because of the supply situation in Mexico," it added.
Balaglitazone R&D costs to be shared by co-developer: DRL
Dec 04, 2007 at 15:16 | Source:
CNBC-TV18
Saumen Chakraborty, CFO, Dr Reddy's Labs said that the Betapharm side of the business faced supply problems from Salutas and added that they have now reduced their dependence on Salutas. On R&D expenses incurred on Balaglitazone which is in phase III of clinical trials, he said they are being shared by the co-developers.
See 20% growth despite Re rise: Dr Reddy's
Jun 25, 2007 at 11:00
GV Prasad, Vice Chairman and CEO at Dr Reddy's Laboratories has said that a significant part of their business comes from the US but the rising Rupee is expected to hit margins.
DRL sees FY09 revenues up 25% at Rs 6250 cr
Sep 12, 2008 at 15:45 | Source:
NewsWire18
Saumen Chakraborty, CFO, Dr Reddy's sees his company's FY09 revenues up by 25% at Rs 6,250 crore, reports CNBC-TV18, quoting NewsWire18. He said that the Dow and BASF units will add Rs 220 crore to FY09 revenues. He feels that the pressure in Europe is still a worry. The company will end pact with German company Salutas in October, he said.
Not dependent on SALUTAS any more: DRL
May 20, 2008 at 17:57 | Source:
CNBC-TV18
GV Prasad, VC & CEO, Dr Reddy's Labs said it is not dependent on SALUTAS any more, reports CNBC-TV18. "We will see improvement in the coming quarters. The Custom Pharmaceutical Services, or CPS, involves making drugs and ingredients specifically for other companies, business saw a de-growth because of the supply situation in Mexico," it added.
DRL targets 25% rev growth in FY09
May 20, 2008 at 19:35 | Source:
CNBC-TV18
Satish Reddy, MD, Dr Reddy's Labs said that dependence on SALUTAS has significantly reduced, especially in the last quarter. He expects the company to grow at 25% in FY09, without any of the upsides or exceptional items.
Balaglitazone R&D costs to be shared by co-developer: DRL
Dec 04, 2007 at 15:16 | Source:
CNBC-TV18
Saumen Chakraborty, CFO, Dr Reddy's Labs said that the Betapharm side of the business faced supply problems from Salutas and added that they have now reduced their dependence on Salutas. On R&D expenses incurred on Balaglitazone which is in phase III of clinical trials, he said they are being shared by the co-developers.
See 20% growth despite Re rise: Dr Reddy's
Jun 25, 2007 at 11:00
GV Prasad, Vice Chairman and CEO at Dr Reddy's Laboratories has said that a significant part of their business comes from the US but the rising Rupee is expected to hit margins.
Videos »
Not dependent on SALUTAS any more: DRL
DRL targets 25% rev growth in FY09
Balaglitazone R&D costs to be shared by co-developer: DRL
See 20% growth despite Re rise: Dr Reddy's
more »
Photos »
/
Follow moneycontrol.com
Facebook
Twitter
Google Plus
RSS
Wap SMS
SMS
Alert
iPad
iPhone
Blackberry
OVI
Android
Window
